Nov 14, 2024 / 01:00PM GMT
Pravin Dugel - Ocular Therapeutix Inc - Executive Chairman, President, CEO
(technical difficulty)
Variability, enhancing patient selection. And we believe strengthening the potential for successful clinical trial outcomes from the onset. We also designed so one and solar to complement each other and boost recruitment for both studies.
Initially, all subjects enrolling in solar were required to be loading or randomization failures. And so one, this approach ensured that solar which is widely seen as the more attractive trial for physicians to enrol their patients in did not cannibalize enrolment in soul one.
As I shared at the outset of my comments today, we're announcing that so one has reached a key enrolment milestone and our trial sites are now enrolling subjects directly into solar.
We expect this important update will lead to further acceleration in solar enrolment which is already well underway as soul one very quickly approaches complete randomization subjects who are not ultimately randomized and seamlessly transition into solar.
This coordinated
Q3 2024 Ocular Therapeutix Inc Earnings Call Transcript
Nov 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers